Dr Ravi Misra Gastroenterologist Limited 12062775 false 2023-07-01 2024-06-30 2024-06-30 The principal activity of the company is Hospital activities and General medical practice activities Digita Accounts Production Advanced 6.30.9574.0 true true 12062775 2023-07-01 2024-06-30 12062775 2024-06-30 12062775 bus:OrdinaryShareClass1 2024-06-30 12062775 bus:OrdinaryShareClass2 2024-06-30 12062775 bus:OrdinaryShareClass3 2024-06-30 12062775 bus:OrdinaryShareClass4 2024-06-30 12062775 core:CurrentFinancialInstruments 2024-06-30 12062775 core:CurrentFinancialInstruments core:WithinOneYear 2024-06-30 12062775 core:FurnitureFittingsToolsEquipment 2024-06-30 12062775 core:OtherPropertyPlantEquipment 2024-06-30 12062775 bus:SmallEntities 2023-07-01 2024-06-30 12062775 bus:AuditExemptWithAccountantsReport 2023-07-01 2024-06-30 12062775 bus:FilletedAccounts 2023-07-01 2024-06-30 12062775 bus:SmallCompaniesRegimeForAccounts 2023-07-01 2024-06-30 12062775 bus:RegisteredOffice 2023-07-01 2024-06-30 12062775 bus:Director1 2023-07-01 2024-06-30 12062775 bus:OrdinaryShareClass1 2023-07-01 2024-06-30 12062775 bus:OrdinaryShareClass2 2023-07-01 2024-06-30 12062775 bus:OrdinaryShareClass3 2023-07-01 2024-06-30 12062775 bus:OrdinaryShareClass4 2023-07-01 2024-06-30 12062775 bus:PrivateLimitedCompanyLtd 2023-07-01 2024-06-30 12062775 core:FurnitureFittingsToolsEquipment 2023-07-01 2024-06-30 12062775 core:OfficeEquipment 2023-07-01 2024-06-30 12062775 core:OtherPropertyPlantEquipment 2023-07-01 2024-06-30 12062775 core:PlantMachinery 2023-07-01 2024-06-30 12062775 countries:UnitedKingdom 2023-07-01 2024-06-30 12062775 2023-06-30 12062775 core:FurnitureFittingsToolsEquipment 2023-06-30 12062775 core:OtherPropertyPlantEquipment 2023-06-30 12062775 2022-07-01 2023-06-30 12062775 2023-06-30 12062775 bus:OrdinaryShareClass1 2023-06-30 12062775 bus:OrdinaryShareClass2 2023-06-30 12062775 bus:OrdinaryShareClass3 2023-06-30 12062775 bus:OrdinaryShareClass4 2023-06-30 12062775 core:CurrentFinancialInstruments 2023-06-30 12062775 core:CurrentFinancialInstruments core:WithinOneYear 2023-06-30 12062775 core:FurnitureFittingsToolsEquipment 2023-06-30 12062775 core:OtherPropertyPlantEquipment 2023-06-30 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 12062775

Dr Ravi Misra Gastroenterologist Limited

Unaudited Filleted Abridged Financial Statements

for the Year Ended 30 June 2024

 

Dr Ravi Misra Gastroenterologist Limited

Contents

Company Information

1

Abridged Balance Sheet

2 to 3

Notes to the Unaudited Abridged Financial Statements

4 to 9

 

Dr Ravi Misra Gastroenterologist Limited

Company Information

Director

Dr Ravi Misra

Registered office

21 Vaughan Avenue, London,
United Kingdom,
NW4 4HT

Accountants

Charles Rippin and Turner Limited
Charles Rippin & Turner
Middlesex House
130 College Road
Harrow
Middlesex
HA1 1BQ

 

Dr Ravi Misra Gastroenterologist Limited

(Registration number: 12062775)
Abridged Balance Sheet as at 30 June 2024

Note

2024
£

2023
£

Fixed assets

 

Tangible assets

4

22,570

36,853

Current assets

 

Debtors

42,109

-

Cash at bank and in hand

 

47,892

136,294

 

90,001

136,294

Creditors: Amounts falling due within one year

(18,671)

(77,498)

Net current assets

 

71,330

58,796

Total assets less current liabilities

 

93,900

95,649

Accruals and deferred income

 

(1,890)

(3,150)

Net assets

 

92,010

92,499

Capital and reserves

 

Called up share capital

5

100

100

Retained earnings

91,910

92,399

Shareholders' funds

 

92,010

92,499

For the financial year ending 30 June 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

All of the company’s members have consented to the preparation of an Abridged Balance Sheet in accordance with Section 444(2A) of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the director has not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the director on 17 July 2024
 

 

Dr Ravi Misra Gastroenterologist Limited

(Registration number: 12062775)
Abridged Balance Sheet as at 30 June 2024

.........................................
Dr Ravi Misra
Director

 

Dr Ravi Misra Gastroenterologist Limited

Notes to the Unaudited Abridged Financial Statements for the Year Ended 30 June 2024

1

General information

The company is a private company limited by share capital, incorporated in United Kingdom.

The address of its registered office is:
21 Vaughan Avenue, London,
United Kingdom,
NW4 4HT

These financial statements were authorised for issue by the director on 17 July 2024.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These abridged financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These abridged financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Going concern

The financial statements have been prepared on a going concern basis.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

 

Dr Ravi Misra Gastroenterologist Limited

Notes to the Unaudited Abridged Financial Statements for the Year Ended 30 June 2024

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Office equipment

20% WDV

Plant and machinery

20% WDV

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Borrowings

 

Dr Ravi Misra Gastroenterologist Limited

Notes to the Unaudited Abridged Financial Statements for the Year Ended 30 June 2024

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

3

Staff numbers

The average number of persons employed by the company (including the director) during the year, was 1 (2023 - 1).

 

Dr Ravi Misra Gastroenterologist Limited

Notes to the Unaudited Abridged Financial Statements for the Year Ended 30 June 2024

4

Tangible assets

Furniture, fittings and equipment
 £

Other tangible assets
£

Total
£

Cost or valuation

At 1 July 2023

800

43,245

44,045

Disposals

-

(6,520)

(6,520)

At 30 June 2024

800

36,725

37,525

Depreciation

At 1 July 2023

473

6,719

7,192

Charge for the year

65

14,218

14,283

Eliminated on disposal

-

(6,520)

(6,520)

At 30 June 2024

538

14,417

14,955

Carrying amount

At 30 June 2024

262

22,308

22,570

At 30 June 2023

327

36,526

36,853

5

Share capital

Allotted, called up and fully paid shares

2024

2023

No.

£

No.

£

Ordinary shares - 75 A of £1 each

75

75

75

75

Ordinary shares - 9 B of £1 each

9

9

9

9

Ordinary shares - 8 C of £1 each

8

8

8

8

Ordinary shares - 8 D of £1 each

8

8

8

8

100

100

100

100

6

Dividends

Interim dividends paid

 

Dr Ravi Misra Gastroenterologist Limited

Notes to the Unaudited Abridged Financial Statements for the Year Ended 30 June 2024

2024
£

2023
£

Interim dividend of 5,100.00 (2023 - 20.00) per each Ordinary Shares

51,000

2,000

 

 

7

Related party transactions

 

Dr Ravi Misra Gastroenterologist Limited

Notes to the Unaudited Abridged Financial Statements for the Year Ended 30 June 2024

Director's remuneration

The director's remuneration for the year was as follows:

2024
£

2023
£

Compensation for loss of office

16,611

5,211